CIRM blog

Meeting the scientists who are turning their daughter’s cells into a research tool

There’s nothing like a face-to-face meeting to really get to know someone. And when the life of someone you love is in the hands of that person, then it’s a meeting that comes packed with emotion and importance. Last week Gay and Steve Grossman got to meet the people who are working with their daughter Lilly’s stem cells. Lilly was …

CIRM

Patient Advocate Leads Drive to Add Rare Diseases to CIRM’s Stem Cell Bank

November 1, 2016 Oakland, CA – Christina Waters is a rare kind of person: creative, compassionate, and committed to creating change. Now she is using those rare talents to help children battling rare diseases. She is helping add blood and skin samples from these children to be turned into stem cells and used as a resource for researchers to better understand …

The Expanding Realm of Regenerative Medicine

Brock Reeve of Harvard Stem Cell Institute discusses ‘ the expanding realm of regenerative medicine ‘ in his 2015 presentation . In this presentation, learn about regenerative medicine as a treatment approach for diseases like diabetes and heart disease. Download this presentation to understand more about: Stem cells on multiple fronts Injectable cryogel-based whole-cell cancer vaccines Genome editing applications Hyrdrogels …

Parexel whitepaper

Three steps for filling the real- world evidence gaps

By Matthew Gordon and Kim Maguire-Wright, PAREXEL® INTERNATIONAL Today, payers and other stakeholders are demanding more (and more robust) real-world evidence (RWE) of a drug’s effectiveness and benefits. It’s understood that randomized clinical trials (RCTs), designed for regulatory approval, don’t provide a true picture of what happens in the real world. The Catch-22 is that payers would like RWE before they place a product on a formulary, …

Pfizer acquisition of cancer drug company could advance oncology research

Published Online: Aug 23,2016 Laurie Toich, Assistant Editor Pfizer recently announced its plans to acquire Medivation, a biopharmaceutical company that develops molecules for oncology. Recent health insurer mergers could have deterred the $14 billion deal, but Pfizer and Medivation’s boards of directors approved the merger, and expect that shares will increase immediately, according to a press release from Pfizer. “The proposed …

Rising costs may not be a result of orphan drugs

Published Online: Sep 12,2016 Laurie Toich, Assistant Editor From Daraprim’s price rising 5556% by Turing Pharmaceuticals under the leadership of Martin Shkreli, to the most recent pricing scandal with Mylan’s EpiPen, Americans have been faced with high out-of-pocket costs for many prescription drugs. Government institutions, such as the US Centers for Medicare and Medicaid, have begun crafting novel ways to reduce …

Rare diseases

Sharing the mission to conquer rare diseases

Closer collaboration between pharmaceutical companies and patient organizations will accelerate drug development At an ever-quickening pace, biopharmaceutical companies and patient advocacy groups are banding together to hasten development of new drugs for rare diseases. Advocacy groups rely on their partners for financial and scientific support while providing access to repositories of patient data – the key to understanding rare diseases …

5 minutes with Dr Subhadra Dravida, Founder and CEO of Transcell

Transcell Biologics is an innovative biotech company focuses in anti-cancer treatment, neurological ailments and autoimmune disorder. The innovative, stem cell based biotech company is based in Hyderabad, India. Ahead of this year’s BioPharma India 2016, we had the pleasure of grabbing a few minutes with its founder and CEO, Dr Subhadra Dravida.   What sparked the establishment of Transcell? We hope to translate stem cell …

Keith Thompson (CGT) announces the creation of Islexa

On day 1 of the World Stem Cells & Regenerative Medicine Congress, Keith Thompson, CEO of the Cell and Gene Therapy Catapult, announced, in partnership with the University of Aberdeen, the creation of a new company: Islexa. Islexa is developing an innovative method to produce laboratory grown islets, which are the organoids in charge of insulin production. This technology holds …